All In Biotech

Drug Trial Radar · NCT00997204

EASSI - Evaluation of the Safety of Self-Administration With Icatibant

Open Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema

Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

151

Actual

Start

Sep 25, 2009

Primary completion

Jun 22, 2011

Study completion Jun 22, 2011

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Jerini AG
First posted
Oct 19, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.

Conditions

  • Hereditary Angioedema

Interventions

  • IcatibantDrug

    Single subcutaneous injection of icatibant, 30 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of IcatibantTime frame: 7 days from the beginning of each phase

Locations

26 sites in 10 countries. Site status is shown where the registry gives one.

  • Hospital Britanico Unidad de Alergia

    Buenos Aires, Argentina

  • Universitätsklinik für Dermatologie und Venerologie

    Graz, Austria

  • Odense Universitetshospital-OUH

    Odense, I Og Alergicentret, Denmark

  • Centre Hospitalier Universitaire/ Service de Dermatologie

    Angers, Angers Cedex 09, France

  • Hospital Edouaed Herriot

    Lyon, Cedex 03, France

  • Clinique Universitaire de Medicine/ Centre National de reference

    Grenoble, Grenoble Cedex 09, France

  • Hopital Claude Huriex/ Service de medicine interne

    Lille, Lille Cedex, France

  • Hopital Europeen Georges Pompidou Immunologie Clinique

    Paris, Paris Cedex 15, France

  • Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, Charité

    Berlin, Germany

  • Universitäts-Hals-Nasen-Ohren-Klinik Essen, Universität Duisburg-Essen

    Essen, Germany

  • Klinkum der Johann Wolfgang Goethe-Universitat

    Frankfurt am Main, Germany

  • Hautklinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität

    Mainz, Germany

  • Bnai-Zion M.C. Clinical Immunology and Allergy Division

    Haifa, Israel

  • Tel Aviv Sourasky Medical Center - Allergy Unit

    Tel Aviv, Israel

  • The Chaim Sheba Medical Center, The Allergy and Clinical Immunology Unit

    Tel HaShomer, Israel

  • Ospedale Luigi Sacco

    Milan, Italy

  • Universita degli Studi di Napoli 'Federico II'

    Naples, Italy

  • Hospital Universitario Vall de Hebrón / Sección de Alergia, Escola Infermeria

    Barcelona, Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain

  • Hospital Universitario La Paz, Servicio de Alergia

    Madrid, Spain

  • Hospital Universitario La Fe, Servicio de Alergia

    Valencia, Spain

  • Luzerner Kantonsspital

    Lucerne, Switzerland

  • Universitätsspital Zürich / Dermatologische Klinik

    Zurich, Switzerland

  • Southmead Hospital, Department of Immunology

    Bristol, United Kingdom

  • Barts & The London NHS Trust, Pathology and Pharmacy Building

    London, United Kingdom

  • Derriford Combined Laboratory, Department of Clinical Immunology & Allergy

    Plymouth, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.